ERBB2 and breast carcinoma: However, this study did not identify HER2 overexpression as an independent risk factor for prognosis in MBC patients (P = 0.083) perhaps due to the gradual widespread use of Herceptin therapy in recent years, improving the prognosis of patients with HER2-positive breast cancer.